Loading…
Loading…
what you think needs to change from a policy perspective to encourage even more uptake of biosimilars.
I'm really trying to understand kind of what's driving the volume. Is it increased penetration into that refractory population?
with the Q code in place, can you help us think about the near-term uptake of PAVBLU in the field?
Can you just talk to me about the level of appetite for additional BD and liver-focused indications such as NASH
If PrEP is removed as a preventative medicine broadly, how does this change your approach to commercialization
Are you seeing more share or competitive share capture from competitive cell therapy products or bispecifics
A year from now on this call, I'd love for you to characterize what you would ask for a good product launch
could you expand on what drives this view and how it has changed since the initiation of the program
can you provide some practical examples of what you and the industry can do to help achieve the goals of getting price parity globally?
Can you provide some additional detail on what FDA wants to see in regard to additional data and what you didn't have from the SUMMIT trial
contextualize the importance of a dual regimen versus the standard of care of bictegravir Biktarvy
can you just talk about the initial feedback, say, versus the competition
I'd love if you could expand on your approach to diligencing assets between Chinese and Western companies